Phase II Study of Ganitumab, a Fully Human Anti-Type-1 Insulin-Like Growth Factor Receptor Antibody, in Patients With Metastatic Ewing Family Tumors or Desmoplastic Small Round Cell Tumors

Grants

Funding Acknowledgements

Supported by Amgen.Employment or Leadership Position: Gregory Friberg, Amgen (C); Hongjie Deng, Amgen (C); Ian McCaffery, Amgen (C); Ian Leitch, Amgen (C); Sunita Badola, Amgen (C); Sung Chang, Amgen (C); Min Zhu, Amgen (C) Consultant or Advisory Role: George Demetri, Amgen (C), Novartis (C), Pfizer (C), Ariad (C), Johnson & Johnson (C), PharmaMar (C), Genentech (C), Infinity Pharmaceuticals (C), EMD-Serono (C), GlaxoSmithKline (C), Daiichi-Sankyo (C), ArQule (C); Anthony Tolcher, Abraxis (C), Amgen (C), Exelixis (C), Genentech (C), GlaxoSmithKline (C), Merck (C), Pfizer (C), Biogen Idec (C), Novartis (C), Regeneron Pharmaceuticals (C), Ariad Pharmaceuticals (C), OrthoBiotec (C) Stock Ownership: Pasquale W. Benedetto, Amgen; Gregory Friberg, Amgen; Hongjie Deng, Amgen; Ian McCaffery, Amgen; Ian Leitch, Amgen; Sunita Badola, Amgen; Sung Chang, Amgen; Min Zhu, Amgen Honoraria: George Demetri, Novartis, Pfizer Research Funding: George Demetri, Pfizer, Ariad, Johnson & Johnson, PharmaMar, Infinity Pharmaceuticals, Amgen, Daiichi-Sankyo; Pasquale W. Benedetto, Amgen; Anthony Tolcher, Amgen, Bristol-Myers Squibb, Genentech, Pfizer, OrthoBiotech, Schering-Plough Research Institute, Biogen Idec, ArQule, Bayer, Merck, Novartis, Array BioPharma Expert Testimony: George Demetri, Ariad (U), Johnson & Johnson (U), PharmaMar (U) Other Remuneration: None